Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$58.27 - $118.99 $35.3 Million - $72.1 Million
-605,587 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$100.76 - $138.36 $14.8 Million - $20.3 Million
-146,437 Reduced 19.47%
605,587 $71.6 Million
Q3 2021

Nov 15, 2021

SELL
$132.37 - $176.78 $147 Million - $196 Million
-1,107,902 Reduced 59.57%
752,024 $101 Million
Q2 2021

Aug 16, 2021

BUY
$60.88 - $161.91 $113 Million - $301 Million
1,859,926 New
1,859,926 $301 Million

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.13B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Darwin Global Management, Ltd. Portfolio

Follow Darwin Global Management, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Darwin Global Management, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Darwin Global Management, Ltd. with notifications on news.